Company Overview
Company Type: Private Company
Website: triumvira.com
Global Number of Employees (Latest): 46
Year Founded: 2015
Total Amount Raised (CAD mm)†: 214.16
Total Rounds of Funding**:3
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Triumvira Immunologics Inc. operates as an immunotherapy company that develops novel T cell therapies for cancer treatments. The company develops novel T cell therapies, including chimeric antigen receptor and engineered T cell receptor therapies and CD19-TAC01, a CD19-directed T cell product for the treatment of B-cell malignancies. It offers Lonza's Cocoon platform for patient-scale cell therapy manufacturing. The company also provides T cell Antigen Coupler, a technology that recruits the entire natural T cell receptor and is independent of the histocompatibility complex, allowing for the development of therapies for a range of patients with solid and liquid malignancies and other diseases. The company was incorporated in 2015 and is based in Austin, Texas with a research facility in Hamilton, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 7.2
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
 46
Net Debt
-
U.S. Number of Employees 2020
 14
U.S. Number of Employees 2019
 9
U.S. Last Year Employee Growth %
 55.6
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Lammers, Paul 
CEO, Secretary & Director
Williamson, Robert Froman
President, CBO, COO & Director
Bramson, Jonathan 
Co-Founder & Chair Scientific Advisory Board
Rill, Donna R.
Chief Technology Officer
Bader, Andreas 
Chief Scientific Officer
Adib, Deyaa 
Chief Medical Officer
Irvin, Jon M.
Senior Vice President of Finance

Key Board Members
Name
Title
Smith, Scott Andrew
Chairman of Board
Lammers, Paul 
CEO, Secretary & Director
Williamson, Robert Froman
President, CBO, COO & Director
Bramson, Jonathan 
Co-Founder & Chair Scientific Advisory Board
Bloom, Brian Matthew
Director
Brenner, Malcolm K.
Member of the Scientific Advisory Board
Brentjens, Renier 
Member of the Scientific Advisory Board
Collins, Cynthia L.
Director
Cooper, Lee 
Director
Eckhardt, Jurgen 
Director
Janse, Daniel 
Director
McMannis, John D.
Member of the Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
9433 Bee Cave Road Building I Suite 240 | Austin, TX | 78733 | United States
Phone: 512 790 0222   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
ATEM Capital
Aug-27-2020
Minority
-
Series A
B Capital Group Management, L.P.
Aug-27-2020
Minority
-
Series A
Bloom Burton & Co., Investment Arm
Aug-27-2020
Unknown
-
Series A
Centre C3i
Aug-27-2020
Unknown
-
Series A
Leaps by Bayer
Aug-27-2020
Minority
-
Series A


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-26-2021
Sep-21-2022
Private Placement
Target
Triumvira Immunologics Inc.


59.74
Aug-27-2020
Mar-17-2022
Private Placement
Target
Triumvira Immunologics Inc.
Leaps by Bayer,Northpond Ventures, LLC,Oceanpine Capital Limited,Viva Biotech Holdings (SEHK:1873),Centre C3i,Bloom Burton & Co., Investment Arm,Multiple Myeloma Research Foundation,Endownment Arm,B Capital Group Management, L.P.,ATEM Capital Buyer Funds:The Myeloma Investment Fund

100.00
Nov-09-2018
Nov-09-2018
Private Placement
Target
Triumvira Immunologics Inc.
Methapharm, Inc.

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-06-2023
Company Conference Presentations
Triumvira Immunologics Inc. Presents at BioFuture 2023, Oct-06-2023 12:30 PM
Sep-18-2023
Company Conference Presentations
Triumvira Immunologics Inc. Presents at BioProcess International Conference & Exhibition, Sep-18-2023
Sep-18-2023
Company Conference Presentations
Triumvira Immunologics Inc. Presents at Cell and Gene Therapy Manufacturing and Commercialization US - 2023, Sep-18-2023
Aug-08-2023
Company Conference Presentations
Triumvira Immunologics Inc. Presents at 11th Annual Immuno-Oncology Summit, Aug-08-2023
Jul-20-2023
Executive/Board Changes - Other
Triumvira Immunologics Appoints Robert Williamson as President, Chief Operating Officer and Member of the Board of Directors


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 06:18 AM
Triumvira Immunologics Inc.
Triumvira Immunologics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
45
GlobalData

Sep 15, 2023 01:11 AM
Triumvira Immunologics Inc.
Triumvira Immunologics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
36
GlobalData

Sep 14, 2023 09:17 PM
Triumvira Immunologics Inc.
Triumvira Immunologics Inc
Reports
94
GlobalData

Jun 16, 2023 07:51 AM
Triumvira Immunologics Inc.
Triumvira Immunologics Inc
Reports
93
GlobalData

Jun 16, 2023 07:50 AM
Triumvira Immunologics Inc.
Triumvira Immunologics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
39
GlobalData

Jun 09, 2023 04:09 AM
Triumvira Immunologics Inc.
Triumvira Immunologics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
34
GlobalData

Mar 17, 2023 05:48 AM
Triumvira Immunologics Inc.
Triumvira Immunologics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
39
GlobalData

Mar 14, 2023 02:31 AM
Triumvira Immunologics Inc.
Triumvira Immunologics Inc
Reports
91
GlobalData

Mar 10, 2023 01:29 AM
Triumvira Immunologics Inc.
Triumvira Immunologics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
33
GlobalData

Dec 13, 2022 12:15 AM
Triumvira Immunologics Inc.
Triumvira Immunologics Inc
Reports
89


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Upcoming Events
Date/Time
Type
Oct-11-2023
Conferences
Oct-13-2023 12:30 PM (EST)
Company Conference Presentations
Oct-19-2023
Conferences
* Future Events are subject to change.

Key Board Members Details
Name
Title
Phone
Fax
Email
Smith, Scott Andrew
Chairman of Board
512 790 0222
-

Lammers, Paul 
CEO, Secretary & Director
512 790 0222
-

Williamson, Robert Froman
President, CBO, COO & Director
512 790 0222
-

Bramson, Jonathan 
Co-Founder & Chair Scientific Advisory Board
512 790 0222
-

Bloom, Brian Matthew
Director
(416) 640-7580
-
bbloom@bloomburton.com
Brenner, Malcolm K.
Member of the Scientific Advisory Board
512 790 0222
-
mbrenner@bcm.edu
Brentjens, Renier 
Member of the Scientific Advisory Board
512 790 0222
-

Collins, Cynthia L.
Director
512 790 0222
-

Cooper, Lee 
Director
512 790 0222
-
lee.cooper@bayer.com
Eckhardt, Jurgen 
Director
512 790 0222
-
JuergenEckhardt@bayer.com
Janse, Daniel 
Director
512 790 0222
-

McMannis, John D.
Member of the Scientific Advisory Board
512 790 0222
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Lammers, Paul 
CEO, Secretary & Director
512 790 0222
-

Williamson, Robert Froman
President, CBO, COO & Director
512 790 0222
-

Bramson, Jonathan 
Co-Founder & Chair Scientific Advisory Board
512 790 0222
-

Rill, Donna R.
Chief Technology Officer
512 790 0222
-

Bader, Andreas 
Chief Scientific Officer
512 790 0222
-

Adib, Deyaa 
Chief Medical Officer
512 790 0222
-

Irvin, Jon M.
Senior Vice President of Finance
512 790 0222
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
